Six months into a blinded Phase 1b trial, ProMIS Neurosciences is reporting positive interim safety and biomarker data for PMN310 in early Alzheimer’s diseaseAlzheimer’s disease, and the figure that matters most is the one conspicuously absent: no ARIA signals. That absence is the entire strategic thesis of the program. Where approved amyloid-targeting antibodies carry meaningful rates of amyloid-related imaging abnormalities, brain swelling and microhemorrhages that complicate dosing and demand intensive MRI surveillance, PMN310 was engineered from the ground up to avoid that liability.
The mechanism behind that design is selective binding. PMN310 is a humanized IgG1 monoclonal antibody targeting toxic amyloid-beta oligomers specifically, not the fibrillar plaques that cover vessel walls and appear to drive ARIA when cleared aggressively. The logic is that a narrower target means a safer clearance profile. Six-month blinded interim data in the PRECISE-AD randomized, double-blind, placebo-controlled, multiple ascending dose study are now being characterized as positive on both safety and biomarker dimensions, though full unblinded readouts will be needed before anyone can draw efficacy conclusions. What the interim framing does confirm is that the DSMB or independent safety reviewers saw nothing that warranted stopping or pausing the trial, which at Phase 1b is the foundational requirement before anything else matters.
The competitive context here is genuinely consequential. The FDA traditionally approved donanemab in July 2024, and lecanemab and aducanumab are also part of the approved landscape, meaning physicians now have real-world experience with ARIA management and its costs: frequent imaging, dose holds, patient anxiety, and access friction driven by risk stratification by APOE4 genotype. If PMN310 can demonstrate a clean ARIA profile through dose escalation and into later efficacy studies, it repositions the entire tolerability calculus for anti-amyloid therapy, particularly for APOE4 carriers currently treated with heightened caution.
The single marker to track from here is what the biomarker data actually show when unblinded. Fluid biomarkers such as plasma p-tau217 or amyloid PET signal shifts would tell the field whether oligomer-selective targeting moves the biology enough to justify continued development. Safety at six months is necessary; target engagement at the same timepoint is what determines whether this program earns a Phase 2.
Source link: https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
